Shares of Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low during mid-day trading on Friday. The company traded as low as C$0.09 and last traded at C$0.09, with a volume of 62000 shares changing hands. The stock had previously closed at C$0.09.
Resverlogix Stock Down 5.6%
The firm has a market capitalization of C$29.26 million, a PE ratio of -2.12 and a beta of 0.12. The company has a debt-to-equity ratio of -82.47, a quick ratio of 0.04 and a current ratio of 0.04. The firm’s 50-day moving average is C$0.10 and its 200 day moving average is C$0.10.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Further Reading
- Five stocks we like better than Resverlogix
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
